In Good Company with Nicolai Tangen HIGHLIGHTS: Emma Walmsley - CEO of GSK
Apr 4, 2025
Emma Walmsley, CEO of GSK and a leader in the pharmaceutical sector, shares fascinating insights on drug discovery and company culture. She discusses GSK's innovative advancements in cancer treatments and HIV therapies. Emma highlights the transformative role of AI in speeding up drug development. She emphasizes the importance of balancing drug accessibility and pricing, alongside the necessity of curiosity and partnership in navigating change. Tune in for her vision on reshaping healthcare for billions around the globe!
AI Snips
Chapters
Transcript
Episode notes
Promising Research Areas
- GSK focuses on impactful innovations in oncology, infectious diseases, respiratory immunology, and HIV.
- They are pioneering new technology platforms like antibody drug conjugates and oligonucleotides.
Value of Vaccines
- Vaccines prevent diseases and offer high returns on investment in healthcare.
- GSK combines science, technology, and talent to stay ahead of diseases.
AI in Pharmaceuticals
- AI is used in clinical trial design, outcome prediction, and tracking infectious diseases.
- Pharmaceutical companies are still in the early stages of utilizing AI's full potential.